GRIN1

Glutamate receptor ionotropic, NMDA 1 · Q05586 · GRIN1 on Sugi Atlas →

215,624 patent compounds predicted against GRIN1, 109,644 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL103515	0.68	15/20
Ditolylguanidine (SCHEMBL80339)	1.00	14/20
SCHEMBL27318	0.54	14/20
Guanabenz (SCHEMBL15390)	0.65	11/20
Memantine (SCHEMBL2688)	1.00	10/20
Memantine (SCHEMBL2689)	1.00	10/20
Memantine (SCHEMBL3053)	1.00	10/20
Levorphanol (SCHEMBL24335)	1.00	9/20
Racemorphan (SCHEMBL46201)	1.00	9/20
Radiprodil (SCHEMBL99256)	1.00	9/20
SCHEMBL106036	0.45	9/20
SCHEMBL72366	0.43	9/20
Dextromethorphan (SCHEMBL29949)	1.00	8/20
Levomethorphan (SCHEMBL29950)	1.00	8/20
Tacrine (SCHEMBL3270)	0.97	8/20
SCHEMBL45769	0.68	8/20
SCHEMBL10673	0.53	8/20
SCHEMBL103596	0.44	8/20
SCHEMBL78658	1.00	7/20
SCHEMBL105665	0.43	7/20

Clinical trials — most relevant to GRIN1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome	PHASE3	UNKNOWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia	PHASE2	COMPLETED
NMDA Modulation in Major Depressive Disorder	PHASE2	RECRUITING
Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects	PHASE2	COMPLETED
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression	EARLY_PHASE1	RECRUITING
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
Effect of D-cycloserine on Extinction of Fear Conditioning	nan	COMPLETED
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis	nan	RECRUITING
Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GRIN1 binder may also engage these)

Protein	Name	Similarity
P35438	—	1.000	P35438 →
P35439	—	1.000	P35439 →
A0A1L8F5J9	—	1.000	A0A1L8F5J9 →
Q5R1P0	—	0.999	Q5R1P0 →
Q9WV18	—	0.965	Q9WV18 →
GABBR1	Gamma-aminobutyric acid type B receptor subunit 1	0.964	landscape →
Q9Z0U4	—	0.961	Q9Z0U4 →
Q9NQX3	—	0.940	Q9NQX3 →
Q9DC16	—	0.936	Q9DC16 →
ERGIC1	Endoplasmic reticulum-Golgi intermediate compartment protein 1	0.935	landscape →
Q03555	—	0.933	Q03555 →
Q8BUV3	—	0.932	Q8BUV3 →
Q8R4D1	—	0.931	Q8R4D1 →
Q13888	—	0.931	Q13888 →
OGT	UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit	0.931	landscape →
Q27HV0	—	0.930	Q27HV0 →
P56558	—	0.930	P56558 →
Q8CGY8	—	0.930	Q8CGY8 →
Q8C6G8	—	0.929	Q8C6G8 →
Q9PW38	—	0.929	Q9PW38 →
Q6P1K8	—	0.928	Q6P1K8 →
P81436	—	0.926	P81436 →
Q4L208	—	0.926	Q4L208 →
Q5SP67	—	0.925	Q5SP67 →
Q6IQT4	—	0.925	Q6IQT4 →
Q5ZJ75	—	0.924	Q5ZJ75 →
Q6IR75	—	0.924	Q6IR75 →
P61202	—	0.924	P61202 →
P79101	—	0.924	P79101 →
Q9Y2E8	—	0.924	Q9Y2E8 →